After roping in $175M+ at the beginning of the year, Metagenomi opens the doors to a new manufacturing site
The gene editing biotech Metagenomi has been on a roll for the past few years. Coming out of the gate in 2020, it had $65 million in cash from Bayer’s investment arm, and just this year it brought in a $175 million Series B. Now it has taken the next step and opened a GMP manufacturing facility on its 50,000 square-foot campus in Emeryville, CA.
The facility, which will have two clean rooms and a modular design, will aim to produce the biotech’s gene editing tools as well as scale up the production of nucleases for either partnered or in-house therapeutic programs.
Metagenomi COO Jian Irish told Endpoints News that the company went ahead with building a new GMP facility as it will allow it to gain expertise in CMC development.
“In the cell and gene therapy space, CMC development has emerged as one of the important topics for many companies in this space as was with the regulatory agencies. So, we believe it is very important for us early on to amass CMC expertise,” Irish said.
Irish said Metagenomi only took a year to finish construction on the facility, and with it being fully integrated into its campus, it will allow the company to translate its research into a clinical setting faster and more seamlessly. However, Irish did not disclose the total cost of the facility to Endpoints. Production at the facility is slated to begin later this year.
As for the employee count at the GMP facility, Irish said that Metagenomi currently has 30 workers employed but would like that number to climb to around 50.
The new facility is a critical step Metagenomi, Irish noted, and will be key in producing its gene editing programs in the months and years ahead.
“So, when the time comes, when we’re ready for IND filing, the CMC module will be ready to go,” Irish said. “I think that timing is very important for (us) as we build the clinical pipeline.”